142 related articles for article (PubMed ID: 7981016)
21. Pharmacokinetics and acetylation of sulfa-2-monomethoxine in humans.
Vree TB; Beneken Kolmer WJ; Hekster YA; Shimoda M; Ono M; Miura T
Biopharm Drug Dispos; 1992 Jan; 13(1):55-68. PubMed ID: 1554877
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics, N1-glucuronidation and N4-acetylation of sulfadimethoxine in man.
Vree TB; Beneken Kolmer EW; Martea M; Bosch R; Hekster YA; Shimoda M
Pharm Weekbl Sci; 1990 Apr; 12(2):51-9. PubMed ID: 2336339
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, N1-glucuronidation, and N4-acetylation of sulfa-6-monomethoxine in humans.
Vree TB; Beneken Kolmer EW; Hekster YA; Shimoda M; Ono M; Miura T
Drug Metab Dispos; 1990; 18(6):852-8. PubMed ID: 1981528
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics, metabolism, and renal excretion of sulfadimidine and its N4-acetyl and hydroxy metabolites in humans.
Vree TB; Hekster YA; Nouws JF; Baakman M
Ther Drug Monit; 1986; 8(4):434-9. PubMed ID: 3824429
[TBL] [Abstract][Full Text] [Related]
25. Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.
Vree TB; O'Reilly WJ; Hekster YA; Damsma JE; van der Kleijn E
Clin Pharmacokinet; 1980; 5(3):274-94. PubMed ID: 7389236
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, N1-glucuronidation and N4-acetylation of sulfamethomidine in humans.
Vree TB; Beneken Kolmer EW; Hekster YA
Pharm Weekbl Sci; 1991 Oct; 13(5):198-206. PubMed ID: 1749708
[TBL] [Abstract][Full Text] [Related]
27. N-acetyl-L-gamma-glutamyl derivatives of p-nitroaniline, sulphamethoxazole and sulphamethizole for kidney-specific drug delivery in rats.
Murakami T; Kohno K; Yumoto R; Higashi Y; Yata N
J Pharm Pharmacol; 1998 May; 50(5):459-65. PubMed ID: 9643438
[TBL] [Abstract][Full Text] [Related]
28. The hydroxylamine of sulfamethoxazole and adverse reactions in patients with acquired immunodeficiency syndrome.
Lee BL; Delahunty T; Safrin S
Clin Pharmacol Ther; 1994 Aug; 56(2):184-9. PubMed ID: 8062495
[TBL] [Abstract][Full Text] [Related]
29. Disposition of drugs in cystic fibrosis. I. Sulfamethoxazole and trimethoprim.
Hutabarat RM; Unadkat JD; Sahajwalla C; McNamara S; Ramsey B; Smith AL
Clin Pharmacol Ther; 1991 Apr; 49(4):402-9. PubMed ID: 2015729
[TBL] [Abstract][Full Text] [Related]
30. Kinetic discrimination of three sulfamethazine acetylation phenotypes.
Chapron DJ; Kramer PA; Mercik SA
Clin Pharmacol Ther; 1980 Jan; 27(1):104-13. PubMed ID: 7351110
[TBL] [Abstract][Full Text] [Related]
31. Oral bioavailability of sulphonamides in ruminants: a comparison between sulphamethoxazole, sulphatroxazole, and sulphamerazine, using the dwarf goat as animal model.
Rátz V; Maas R; Semjén G; van Miert AS; Witkamp RF
Vet Q; 1995 Sep; 17(3):82-7. PubMed ID: 8525600
[TBL] [Abstract][Full Text] [Related]
32. Isoniazid pharmacokinetics in children according to acetylator phenotype.
Rey E; Gendrel D; Treluyer JM; Tran A; Pariente-Khayat A; d'Athis P; Pons G
Fundam Clin Pharmacol; 2001 Oct; 15(5):355-9. PubMed ID: 11903505
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the pharmacokinetics of sulfamethoxazole in male chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study.
Li XY; Gao F; Li ZQ; Guan W; Feng WL; Ge RL
Clin Ther; 2009 Nov; 31(11):2744-54. PubMed ID: 20110016
[TBL] [Abstract][Full Text] [Related]
34. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects.
May DG; Porter JA; Uetrecht JP; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1990 Dec; 48(6):619-27. PubMed ID: 2249373
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of a sulphamethoxazole/trimethoprim formulation in pigs after intravenous administration.
Nouws JF; Vree TB; Degen M; Mevius D
Vet Q; 1991 Jul; 13(3):148-54. PubMed ID: 1949541
[TBL] [Abstract][Full Text] [Related]
36. Adverse reactions to co-trimoxazole in HIV infection: a reappraisal of the glutathione-hydroxylamine hypothesis.
van der Ven AJ; Vree TB; Koopmans PP; van der Meer JW
J Antimicrob Chemother; 1996 May; 37 Suppl B():55-60. PubMed ID: 8818829
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of the trimethoprim-sulphamethoxazole combination in the elderly.
Varoquaux O; Lajoie D; Gobert C; Cordonnier P; Ducreuzet C; Pays M; Advenier C
Br J Clin Pharmacol; 1985 Dec; 20(6):575-81. PubMed ID: 3879182
[TBL] [Abstract][Full Text] [Related]
38. Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans.
Buchwald P; Juhász A; Bell C; Pátfalusi M; Howes J; Bodor N
J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):377-400. PubMed ID: 16320099
[TBL] [Abstract][Full Text] [Related]
39. Acetylation, deacetylation and hydroxylation of sulphamethoxazole and N4-acetylsulphamethoxazole in the turtle Pseudemys scripta elegans.
Vree TB; Vree JB; Hekster YA; Nouws JF
Vet Q; 1987 Oct; 9(4):381-4. PubMed ID: 3424645
[TBL] [Abstract][Full Text] [Related]
40. N-acetylation and oxidative capacity in aged volunteers determined with sulfamethazine and antipyrine.
Siegmund W; Franke G; Wulkow R; Hanke W; Thonack R
Int J Clin Pharmacol Ther Toxicol; 1991 Dec; 29(12):469-73. PubMed ID: 1813431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
